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Purpose: To evaluate the effectiveness of tramadol for the reduction of pain in panretinal photocoagulation (PRP).
Methods: A double-masked randomized controlled study was performed. Fifty-eight eyes in 29 patients with proliferative 
diabetic retinopathy were enrolled. The eyes of the patients were randomized into two groups. Group A received an 
empty capsule. Group B received an oral intake of 100 mg tramadol. The capsule used in Group A had the same 
appearance as that used in Group B. Pain during PRP was assessed using a visual analog scale. Vital signs, 
including blood pressure and heart rate, were measured.
Results: The mean pain scores for groups A and B were 4.80±2.10 and 3.83±1.82 (p=0.09). There were no significant 
differences in the mean pain scores between the two groups. More patients in group A complained of greater pain 
than moderate intensity (visual analogue scale=4). Systemic blood pressure increased significantly in group A after 
laser treatment. However, there were no significant differences in the diastolic blood pressure changes between 
the two groups. We found no statistical correlation in the heart rate changes.
Conclusions: We failed to prove that tramadol is effective for pain relief because of the small sample size. However, 
tramadol was effective for the relief of more severe pain. It was also found to stabilize vital sign changes, such as 
systolic blood pressure during PRP.
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Diabetic retinopathy remains the most common cause of 
blindness in the working age population in the developed 
world. Findings from the Diabetic Retinopathy Study (DRS) 
established that panretinal photocoagulation (PRP) is an effec-
tive treatment for reducing severe visual loss in patients with 
proliferative diabetic retinopathy.
1 However, most patients 
experience pain during PRP.
2-4 Intolerance to laser treat-
ment can be increased because of pain.
2 Therefore, steps 
are needed to reduce pain during PRP. 
Retrobulbar anesthesia is an effective way to block pain 
sensation. However, it is invasive, has potential complications, 
and is difficult to apply in an outpatient room.
5 Intramuscular 
administration of anesthetic agents can be effective, but some 
patients have a phobia for injections. Oral analgesia is widely 
used in other areas of pain control. Analgesia can reduce pain 
by the sustained excitation of dorsal horn neurons. Pain may 
be eliminated or reduced if the afferent barrage is prevented 
or reduced from reaching the CNS by either a pre-injury 
neuronal block with local anesthetics or the use of other 
analgesics prior to a nociceptive input.
6,7
Tramadol is an atypical opioid that is used to treat moderate 
and severe pain. The mechanism of action of tramadol is not 
yet fully understood, but it is believed to work through the 
modulation of the GABAergic, noradrenergic, and serotoner-
gic systems. In addition, tramadol is a mild μ-opioid receptor 
agonist. As with many opioids, tramadol has the ability to 
create dependence, but this risk is lower than with traditional 
opioids. 
The effects of tramadol on pain reduction during PRP 
have not yet been studied. In this study, we evaluated the 
analgesic effects of tramadol for pain relief during PRP in 
patients with proliferative diabetic retinopathy.
Materials and Methods
A prospective, double masked, randomized, case-controlled 
study was conducted in the department of ophthalmology 
of Hanyang University Guri Hospital. Data from the patients 
was collected between April 2007 and December 2007. In-
formed consent was obtained from all patients prior to their 
participation. The Ethical Committee of the Hanyang Uni-
versity Guri Hospital approved all methodologies. Patients 
with proliferative diabetic retinopathy and no previous history 
of PRP were included. Patients were excluded from the study 
if they had a history of hypersensitivity or contraindication Korean J Ophthalmol Vol.23, No.4, 2009
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Table 1. Pain scores in the two study groups
Group A
* 
(N=32)
Group B
†
(N=24)
p-value
VAS 4.80±2.20 3.83±1.82 0.09
Values are presented as mean±SD.
VAS=visual analog scale.
*Placebo; 
†1T tramadol.
Table 2. Pain scores above and below moderate intensity
in the two groups
VAS Group A
* 
(N=32)
Group B
†
(N=24)
p-value
>4 22 (68.7%) 9 (37.5%)
0.03
≤4 10 (31.3%) 15 (62.5%)
Values are presented as number (%).
VAS=visual analog scale.
*Placebo; 
†1T tramadol.
Table 3. Pain scores for each anatomical area
Group A
*
(N=32)
Group B
†
(N=24)
p-value
Inferior 5.14±2.49 1.00±0.70
0.188
Nasal 4.50±2.12 4.92±1.42
Superior 5.12±2.25 4.17±1.96
Temporal 4.25±2.72 3.12±1.85
Values are presented as mean±SD.
*Placebo; 
†1T tramadol.
Table 4. Hemodynamic changes in each group
Group A
*
(N=32)
Group B
†
(N=24)
p-value
Systolic pressure 33.35±24.16 21.11±13.74 0.048
Diastolic pressure 11.00±10.60 9.00±12.09 0.46
Heart rate 2.10±10.02 -1.05±8.45 0.56
Values are presented as mean±SD.
*Placebo; 
†1T tramadol
to tramadol, a significant psychiatric disorder, a history of 
previous PRP, or the current use of any analgesic medi-
cations (for example, rheumatoid arthritis or malignancy). 
Demographic data, diabetes mellitus (DM) status, duration of 
DM, and the presence of hypertension were also recorded.
One eye from each patient was randomized to a treatment 
group. A control group was created using the fellow eye of 
same patient. Group A received an empty capsule. This cap-
sule had the same appearance as that used in group B. Group 
B received an oral intake of low dose (100 mg) tramadol 
(Tridol
®; Yuhan corporation, Seoul, Korea). The medication 
was administered one hour prior to the panretinal photocoa-
gulation procedure.
The pupils were dilated using 1% tropicamide (1%  My-
diacyl
®; Alcon Laboratories, Hunenberg, Switzerland). One 
hour later, a drop of proparacaine hydrochloride 0.5% (Al-
caine
®; Alcon Laboratories) was applied to each eye for 
corneal anesthesia prior to application of the fundus contact 
lens (Transequator
®; Volk Optical, Mentor, OH, USA). 
Laser treatment using an argon green laser (Novus Omni
® 
; Coherent, Palo Alto, CA, USA) was performed by the 
second researcher. The treatment guidelines were stand-
ardized, as recommended by the Early Treatment Diabetic 
Retinopathy Study.
8 The study involved a total of 800- 
1600 burns. The parameters for the burns consisted of a 
400 μm spot size and 0.15 second pulse duration, attempting 
a moderately white burn avoiding the horizontal midlines. 
The areas were treated in the following order: inferior, 
nasal, superior, and temporal.
Visual acuity and intraocular pressure were measured prior 
to the laser treatment. Blood pressure and heart rate were 
recorded with a digital monitor just before, during, and im-
mediately after the laser treatment.
A visual analog scale (VAS), consisting of a 10 cm scale 
labeled with numbers from 0 to 10, was used to determine 
the intensity of the pain. The blinded examiner instructed 
patients that 0 represents experiencing no pain and 10 repre-
sents experiencing the maximum pain they could imagine. 
The general analgesic effects of tramadol during laser photo-
coagulation were studied in each of the three groups. Changes 
in vital signs were monitored and recorded, and the severities 
of the pain among the areas where the laser was applied were 
recorded.
Statistical computations were performed using SPSS ver. 
11.0 (SPSS Inc., Chicago, IL, USA). A p-value of less than 
0.05 was considered statistically significant.
Results
Twenty-six eyes from 13 patients with proliferative diabetic 
retinopathy were studied, with a total of 32 cases in group 
A and 24 in group B. The mean age of the patients was 
52.90±8.08 years, with a range of 34 to 72 years. All of the 
patients had type Ⅱ diabetes. The duration of diabetes history 
ranged from 1 to 20 years, with a mean of 11.19±6.16 years. 
Thirteen patients had a history of hypertension and were 
taking oral systemic anti-hypertension drugs. Histories of other 
ocular diseases were not reported, except for refractive errors. 
There were no significant differences in the mean pain 
scores between the two treatment groups. The mean pain 
scores for group A and B were 4.80±2.20 and 3.83±1.82 
(p=0.09) (Table 1). In group A, 22 of 32 (68.7%) patients 
felt more severe pain (VAS>4), as compared to the placebo 
group. In group B, 9 of 24 (37.5%) patients felt more severe 
pain, as compared to the placebo group (Table 2). Pain 
score results for the retinal areas where the laser was ap-
plied are summarized on Table 3. 
Systolic and diastolic blood pressures increased after laser 
treatment in all of the groups (Table 4). The increases in 
these pressures in the placebo group were 33.35±24.16 mmHg BW Ko, et al. TRAMADOL FOR PAIN IN PANRETINAL PHOTOCOAGULATION
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and 11.00±10.60 mmHg, respectively. An increase of 21.11 
±13.74 in the systolic pressure, and 9.00±12.09 in the diastolic 
pressure, was noted in group B. A significant difference in 
the change of systolic blood pressure between the two groups 
(p=0.048) was noted.
We found a decrease in the heart rate for patients in group 
B. The mean changes in the heart rate for patients in group 
A and B were 2.10±10.02 and -1.05±8.45, respectively. There 
was no statistical correlation in the heart rate changes between 
the two groups. 
Discussion
Pain experienced during laser therapy varies, but can be 
a serious complication for some patients. In this study, 31 of 
56 patients reported more severe pain (VAS>4), indicating 
that PRP is a painful ophthalmic procedure. These findings 
are similar to those in other studies.
2,4,9
This study evaluated the analgesic effects of tramadol 
during PRP. Tramadol is an analgesic widely used to relieve 
moderate to moderately severe pain. Tramadol is more effec-
tive than acetaminophen and other non-steroidal anti-in-
flammatory drugs (NSAIDs) for pain relief but is considered 
less effective than opioids. The mechanism  of  action  for  tra-
madol involves inhibiting the reuptake of serotonin and 
norepinephrine, as well as exhibiting a weak μ-agonist 
activity.
10 The advantages of tramadol include a relative lack 
of respiratory depression, low risk of major organ  toxicity, 
little depression of gastrointestinal motility, and a low potential 
for abuse.
11-13 Common side effects (overall incidence of 1.6%  to 
6.1%) include dizziness, drowsiness, sweating, nausea, vomit-
ing,  dry  mouth,  and  headache. No differences in pain relief 
between the placebo and tramadol groups during PRP were 
found in this study. However, there were fewer patients in 
the tramadol group who felt more severe pain (VAS>4). and 
tramadol was effective in mitigating the rise in systolic blood 
pressure. 
Controversy over the most effective method of pain control 
during PRP persists. NSAIDs can relieve pain by inhibiting 
cyclooxygenase enzyme activity and, thus, block the for-
mation of endogenous prostaglandins. Ocular administration 
of 0.5% ketorolac tromethamie ophthalmic solution is a 
useful analgesic drug which reduces prostaglandin E2 
levels in the aqueous humor.
14 NSAIDs can be used to treat 
pain after other ocular surgeries, such as photorefractive 
keratectomy,
15 radial keratotomy,
16 and posterior segment 
surgery.
17 Sodium diclofenac 0.1% is effective in reducing 
pain during PRP, as compared with a placebo.
4 However, 
Esgin and Samut.
5 reported that the analgesic effects of top-
ical ketorolac 0.5% were not different than an artificial tear 
drop during posterior segment laser photocoagulation. 
Paracetamol is a widely used and effective analgesic. How-
ever, pre-emptive analgesia with paracetamol did not signi-
ficantly reduce the pain associated with panretinal photocoa-
gulation.
18 Wu et al.
9 evaluated the analgesic effects of 
acetaminophen and found that acetaminophen is not 
effective for pain control. 
Retrobulbar and peribulbar anesthesia, on the other hand, 
have been known to be effective for pain relief,
9 although 
both are invasive and can result in vision-threatening com-
plications, including perforation and infection. Subtenon ane-
sthesia is another method that has fewer risks, as compared 
to retrobulbar and peribulbar anesthesia. Unfortunately, sub-
tenon anesthesia is also dangerous to patients, although no- 
needle, one-quadrant subtenon anesthesia during PRP
  is 
possible.
3 Stevens argued that this method can provide 
effective anesthesia during panretinal photocoagulation and 
avoids the risks of using a sharp needle. 
Entonox gas, a mixture of 50% nitrous oxide and 50% 
oxygen, can also be used to reduce pain during PRP.
2 Ho
wever, in practice, Entonox gas is difficult to use, requirin
g a large amount of equipment and space. 
There were some limitations to this study. First, the sample 
size was small, and the number of patients in each group 
was not the same. Second, the blinded examiner who evaluated 
the visual analog scales from the patients was not one person. 
This could be a source of bias. Third, although most of the 
laser parameters were the same, the number of laser treat-
ments was different for each patient. 
PRP is a painful procedure for most patients and can cause 
changes in vital signs, including blood pressure and heart rate. 
In this study no evidence that tramadol is effective for pain 
relief during PRP was found. However, this study showed 
that tramadol is more effective than a placebo for relieving 
more severe pain and is also effective in stabilizing vital 
signs, such as systolic blood pressure. Further studies are ne- 
eded to evaluate pain control during PRP.
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